SCHEMBL28046606

SCHEMBL28046606

O=C(O)Cc1cc(-c2ccccc2)n[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ CHEK1 O14757 1/20 0.51
▸ RET P07949 1/20 0.51
▸ PDGFRB P09619 1/20 0.51
▸ PIM1 P11309 1/20 0.51
▸ PDGFRA P16234 1/20 0.51
▸ GSK3B P49841 1/20 0.51
▸ RPS6KA3 P51812 1/20 0.51
▸ LIMK1 P53667 1/20 0.51
▸ CDK5 Q00535 1/20 0.51
▸ TYRO3 Q06418 1/20 0.51
▸ MAPK14 Q16539 1/20 0.51
▸ LRRK2 Q5S007 1/20 0.51
▸ AURKB Q96GD4 1/20 0.51
▸ CLK4 Q9HAZ1 1/20 0.51
▸ DYRK1B Q9Y463 1/20 0.51
▸ NR1H4 Q96RI1 1/20 0.51
▸ POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27706536 0.97 TP53 (0.54) TP53LMNAL3MBTL1CHEK1RET
SCHEMBL22191641 0.86 CYP2D6 (0.67) TP53LMNAPIM1NR1H4CYP11B1
SCHEMBL27909176 0.85 CA12 (0.60) NR1H4ACR
Hydrochloric Acid SCHEMBL22320090 0.85 CYP2D6 (0.65) TP53LMNAPIM1NR1H4CYP11B1
SCHEMBL15622965 0.83 NR1H4 (0.72) TP53LMNAL3MBTL1CHEK1RET
SCHEMBL18926448 0.83 GAA (0.58) TP53LMNAL3MBTL1CHEK1RET
SCHEMBL2522379 0.80 LMNA (0.62) TP53LMNAL3MBTL1CHEK1RET
SCHEMBL27894415 0.80 ALPL (0.62) TP53LMNARAB9AMMEALOX15
SCHEMBL7386480 0.78 ALPG (0.51) TP53LMNAL3MBTL1CHEK1RET
SCHEMBL2374361 0.77 LMNA (0.58) TP53LMNAL3MBTL1CHEK1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102906093-B NK-3 receptor selective antagonists compound, pharmaceutical composition and the using method in the receptor-mediated disease of NK-3 EUROSCREEN S.A. (BE) 2016-01-13 — — CN disclosed
Send feedback